Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Nanoscale|December 23, 2025
Phase-engineered 1T'/2H-MoS<sub>2</sub> heterophase junctions for high-performance aqueous zinc-ion batteriesXue-Wei Lu, Xuetao Li, Ruxuan Chen, et al.
Journal of Clinical Medicine|January 11, 2024
The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective StudyHui Huang, Ruxuan Chen, Yan Xu, et al.
Journal of Thoracic Disease|March 12, 2026
Crizotinib attenuates bleomycin-induced pulmonary fibrosis via regulating fibroblast activationYujie Shi, Zhiyi Li, Ruxuan Chen, et al.
Clinical and Experimental Rheumatology|October 3, 2025
Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: a retrospective studyYujie Shi, Ruxuan Chen, Hongli Sun, et al.
Clinical Rheumatology|March 6, 2025
Characteristics and prognostic analysis of Pneumocystis jirovecii pneumonia in connective tissue diseases patients with interstitial lung disease: a retrospective studyYujie Shi, Ruxuan Chen, Hongli Sun, et al.
Clinical Rheumatology|September 21, 2024
Prognostic analysis of Pneumocystis jirovecii pneumonia in patients with systemic vasculitides: a retrospective cohort studyRuxuan Chen, Yujie Shi, Hongli Sun, et al.
Diagnostics (Basel, Switzerland)|December 23, 2022
Prognostic Analysis of Pneumocystis Jirovecii Pneumonia in Interstitial Lung Disease Patients: A Retrospective Clinical StudyYuxin Sun, Chi Shao, Hui Huang, et al.
BMC Immunology|July 11, 2026
Clinical characteristics and risk factors of cytomegalovirus infection in patients with good syndromeQi Chen, Ruxuan Chen, Yujie Shi, et al.
BMC Infectious Diseases|August 28, 2024
Prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus: a retrospective studyYujie Shi, Ruxuan Chen, Hongli Sun, et al.
Clinical and Experimental Rheumatology|July 30, 2025
Clinical adverse events to voclosporin: a real-world drug safety study based on FDA Adverse Event Reporting SystemJiaqi Zhang, Yanjun Wan, Liheng Liu, et al.
Pageof 5